Kalaris Therapeutics (KLRS) Common Equity (2019 - 2026)
Kalaris Therapeutics' Common Equity came in at $57.67 million for Q2 2026, up 8.6% from $53.12 million a year earlier but down 15.9% from the prior quarter.
Powered by 
Analysis
Kalaris Therapeutics (KLRS) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Kalaris Therapeutics' Common Equity was $78.81 million.
- Common Equity carries a five-year compound annual growth rate of -25.9% (FY2020 to FY2025).
- Going back by year, Common Equity was -$96.62 million in FY2024, -$45.02 million in FY2023, $224.52 million in FY2022 (-0.3%) and $225.27 million in FY2021 (-36.2%).
- The five-year range for quarterly Common Equity is -$96.62 million (Q4 2024) to $267.3 million (Q3 2021).
- The fastest year-over-year change in Common Equity over five years came in Q2 2023 (growth of 44.9%), and the weakest in Q2 2022 (a decline of 47.7%).
- Business Quant data shows KLRS's Common Equity at $68.56 million (Q1 2026), $78.81 million (Q4 2025) and $41.87 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Kalaris Therapeutics | 67.84 Mn | 67.84 Mn | - | 57.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.67 Mn |
| Mar 31, 2026 | 68.56 Mn |
| Dec 31, 2025 | 78.81 Mn |
| Sep 30, 2025 | 41.87 Mn |
| Jun 30, 2025 | 53.12 Mn |
| Mar 31, 2025 | 63.87 Mn |
| Dec 31, 2024 | -96.62 Mn |
| Sep 30, 2024 | -89.38 Mn |
| Jun 30, 2024 | -51.53 Mn |
| Mar 31, 2024 | -47.54 Mn |
| Dec 31, 2023 | -45.02 Mn |
| Sep 30, 2023 | 195.33 Mn |
| Jun 30, 2023 | 229.11 Mn |
| Mar 31, 2023 | 193.53 Mn |
| Dec 31, 2022 | 224.52 Mn |
| Sep 30, 2022 | 253.23 Mn |
| Jun 30, 2022 | 158.14 Mn |
| Mar 31, 2022 | 191.68 Mn |
| Dec 31, 2021 | 225.27 Mn |
| Sep 30, 2021 | 267.30 Mn |
API Access
Kalaris Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=KLRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "KLRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=KLRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();